|
Antibody Pharmacokinetics and
Pharmacodynamics Lecture Series, Pfizer, March 2008, Sandwich,
England
Protein Pharmacokinetics,
Allergan Pharmaceuticals, May 2008, Irvine California
Antibody Pharmacokinetics and
Pharmacodynamics Lecture Series, Pfizer, March 2008, Groton,
Connecticut
Introduction to Antibody PK/PD:
Determinants of Mab Absorption, Distribution, and Elimination,
American College of Clinical Pharmacology, Annual Meeting,
September 2007, San Francisco, California
PKPD of Antibodies: Examples,
American College of Clinical Pharmacology, Annual Meeting,
September 2007, San Francisco, California
Comparability Assessment of
Therapeutic Proteins, Amgen, July 2007, Thousand Oaks,
California
Intricacies in Pharmacokinetics
and Pharmacodynamics of Peptides and Proteins, Amgen, July 2007,
Thousand Oaks, California
Pharmacokinetics of Peptides and
Proteins, Amgen, July 2007, Thousand Oaks, California
Bimolecular Interactions in
Dynamics, Amgen, July 2007, Thousand Oaks, California
Target-Mediated Disposition of
Monoclonal Antibodies, Amgen, July 2007, Thousand Oaks,
California
Physiologically-based
Pharmacokinetic Models for Monoclonal Antibodies, Amgen, July
2007, Thousand Oaks, California
Pharmacodynamic Models Relevant
to Proteins, Amgen, July 2007, Thousand Oaks, California
Utility of PK/PD Modeling in the
Comparability Assessment of Therapeutic Proteins – An Academic
Perspective, AAPS National Biotechnology Meeting, June 2007, San
Diego, California
Where Did my Mab Go?, AAPS
National Biotechnology Meeting, June 2007, San Diego, California
Monoclonal Antibody
Pharmacokinetics, Pfizer, June 2007, Groton, Connecticut
PK/PD Considerations for the
Optimization of Immunotoxicotherapy, Pfizer, June 2007, Groton,
Connecticut
PD Models Relevant to Monoclonal
Antibodies, May 2007, Genentech, Pharmacokinetic –
Pharmacodynamic Concepts and Applications Course, San Francisco,
California
Target-Mediated Disposition of
Antibodies, May 2007, Genentech, Pharmacokinetic –
Pharmacodynamic Concepts and Applications Course, San Francisco,
California
Dynamics of Bimolecular
Interactions: Considerations for Immunotoxicotherapy, May 2007,
Genentech, Pharmacokinetic – Pharmacodynamic Concepts and
Applications Course, San Francisco, California
Pharmacokinetics of Peptides and
Proteins, May 2007, Genentech, Pharmacokinetic – Pharmacodynamic
Concepts and Applications Course, San Francisco, California
Pharmacokinetics and
Pharmacodynamics of Monoclonal Antibodies, May 2007, University
at Buffalo, Pharmacokinetic – Pharmacodynamic Concepts and
Applications Course, Buffalo, New York
Monoclonal Antibody
Pharmacokinetics, New York Academy of Sciences, Symposium on The
Future of Monoclonal Antibody Biotherapeutics Production and
Development, May 2007, New York, New York
Alphabet Soup: ITP, IVIG, FcRn,
& Mab PK, May 2007, University of Kentucky, Lexington, Kentucky
Mechanistic Insights into the
ADME Properties of Antibodies and Other Biologics, Merck, March
2007, West Point, Pennsylvania
Target-Mediated Disposition and
Dynamics of Biologics: Principles and Applications, Merck, March
2007, West Point, Pennsylvania
Pharmacokinetics and
Pharmacodynamics of Antibodies: Work Underway in the Balthasar
Laboratory, Amgen, November 2006, Thousand Oaks, California
Monoclonal Antibody
Pharmacodynamics, F.Hoffmann-La Roche Ltd, November 2006, Basel,
Switzerland
Monoclonal Antibody
Pharmacokinetics, F.Hoffmann-La Roche Ltd, November 2006, Basel,
Switzerland
Physiologically-based Modeling:
General Considerations and Examples, Novartis Pharma AG, October
2006, Basel, Switzerland
Investigations of the influence
of FcRn on IgG tissue and systemic disposition, Novartis Pharma
AG, October 2006, Basel, Switzerland
Use of Simulation to Guide the
Selection of Optimal Monoclonal Antibodies for
Immunotoxicotherapy, Novartis Pharma AG, October 2006, Basel,
Switzerland
Pharmacokinetic /
Pharmacodynamic Modeling and Immunotoxicotherapy, Novartis
Pharma AG, October 2006, Basel, Switzerland
Target-Mediated Monoclonal
Antibody Disposition, Novartis Pharma AG, October 2006, Basel,
Switzerland
Monoclonal Antibody
Pharmacokinetics & Pharmacodynamics, Novartis Pharma AG, October
2006, Basel, Switzerland
Monoclonal Antibodies:
Pharmacokinetic & Pharmacodynamic Modeling, Cognigen, September
2006, Amherst, New York
Distribution, Clearance, and
PK/PD Modeling: Special Considerations for Proteins and
Peptides, Merck, June 2006, North Wales, Pennsylvania.
Mab PK Overview, AAPS Workshop
on Current Trends in Monoclonal Antibody Development and
Manufacturing, AAPS National Biotechnology Meeting, June 2006,
Boston, Massachusetts.
Application of FcRn Inhibitors
for the Treatment of Humoral Autoimmune Diseases, AAPS National
Biotechnology Meeting, June 2006, Boston, Massachusetts.
Pharmacokinetics and
Pharmacodynamics of Monoclonal Antibodies, May 2006, University
at Buffalo, Pharmacokinetic – Pharmacodynamic Concepts and
Applications Course, Buffalo, New York
Antibody Pharmacokinetics and
Pharmacodynamics: Focus on Issues Relevant for
Immunotoxicotherapies, May 2006, Wyeth, Collegeville,
Pennsylvania.
PK/PD Correlations of Monoclonal
Antibodies, April 2006, 5th International Symposium
on Measurement and Kinetics of In Vivo Drug Effects,
Noordwijkerhout, The Netherlands.
Antibody Pharmacokinetics, April
2006, Pfizer, Ann Arbor, Michigan.
FcRn Inhibition: An Important
Mechanism for IVIG Effects in ITP? March 2006, Department of
Oral Biology, University at Buffalo, The State University of New
York, Buffalo, New York.
Pharmacokinetic Strategies to
Optimize IP Chemotherapy for Ovarian Cancer, January 2006,
Rutgers University, New Brunswick, New Jersey.
Studies assessing the effects of
an anti-FcRn antibody on the disposition of anti-platelet
antibodies and on anti-platelet antibody-induced
thrombocytopenia in a mouse model of sustained ITP, December
2005, ITP Study Group Meeting (in conjunction with the Annual
Meeting of the American Society of Hematology), Atlanta,
Georgia.
Comparison of anti-RBC
immunotherapy, IVIG, and antibody-cated liposome therapies in a
mouse model of sustained ITP, December 2005, ITP Study Group
Meeting (in conjunction with the Annual Meeting of the American
Society of Hematology), Atlanta, Georgia.
Antibody Pharmacokinetics and
Pharmacodynamics: Are there important differences relative to
small molecule PK/PD?, November 2005, Schering Plough Research
Institute, Kenilworth, New Jersey.
FcRn-inhibition: An important
mechanism for IVIG effects in immune thromobocytopenia?
September 2005, University of Minnesota, Minneapolis, Minnesota
Development of FcRn inhibitors
for autoimmunity, August 2005, Genentech, San Francisco,
California.
Antibody Pharmacokinetics and
Pharmacodynamics, June 2005, Wyeth, Boston, Massachusetts.
Application of pharmacokinetic /
pharmacodynamic modeling to expedite the discovery and
development of monoclonal antibodies for immunotoxicotherapy,
June 2005, National Biotechnology Conference of the American
Association of Pharmaceutical Scientists, San Francisco,
California
Pharmacokinetics and
Pharmacodynamics of Monoclonal Antibodies, May 2005, University
at Buffalo, Pharmacokinetic – Pharmacodynamic Concepts and
Applications Course, Buffalo, New York
Pharmacokinetic Strategies to
Optimize IP Chemotherapy, February 2005, Pharmacology and
Therapeutics Department, Grace Cancer Drug Center, Roswell Park
Memorial Cancer Institute, Buffalo, New York.
Pharmacokinetics and
Pharmacodynamics of Antibodies, January 2005, International
Symposium for Life Sciences and Medicine, Keio University,
Tokyo, Japan.
Mechanisms and Kinetics of IgG
Elimination, November 2004, Sunrise School, Annual Meeting of
the American Association of Pharmaceutical Scientists,
Baltimore, MD
Pharmacokinetics and
Pharmacodynamics of Monoclonal Antibodies, May 2004, University
at Buffalo – Leiden/Amsterdam Center for Drug Research
Pharmacokinetic – Pharmacodynamic Concepts and Applications
Course, Buffalo, New York
Inverse Targeting for
Optimization of Intraperitoneal Chemotherapy, May 2004,
Department of Biopharmaceutical
Inverse Targeting with Anti-Drug
Antibodies, April 2004, University of Kentucky, Division of
Pharmaceutical Sciences, College of Pharmacy, Lexington,
Kentucky
Pharmacodynamic Analyses for
Assessment of Equivalence of Biotech Products, November 2003,
Expert Panel on Complex Activities, United States Pharmacopoeia,
Rockville, Maryland
Competitive Inhibition of FcRn:
An important mechanism of IVIG action?, November 2003, Annual
Meeting of the American Association of Blood Banks, San Diego,
California
Pharmacokinetics and
Pharmacodynamics of Monoclonal Antibodies, May 2003, University
at Buffalo – Leiden/Amsterdam Center for Drug Research
Pharmacokinetic – Pharmacodynamic Concepts and Applications
Course, Buffalo, New York
Application of PK/PD to
Investigate Mechanisms of IVIG Action in ITP, May 2003,
Division of Pharmaceutics, College of Pharmacy, The Ohio State
University, Columbus, Ohio.
Application
of Kinetic/Dynamic Mathematical Models to Guide the Development
of New Therapies of Immune Thrombocytopenia, March 2003,
Department of Chemical Engineering, University of Maryland,
College Park, Maryland.
Pharmacodynamic Analyses for Assessment of Equivalence of
Biotech Products, January 2003, Expert Panel on Complex
Activities, United
States Pharmacopoeia, Rockville, Maryland
Role of FcRn in IgG Metabolism:
Implications for Therapeutic Antibodies and Autoimmunity,
January 2003, Molecular Biopharmaceutics Meeting, Waikiki,
Hawaii
Antibody PK/PD: New Insights &
Applications, November 2002, Buffalo Pharmaceutics Symposium,
University at Buffalo, The State University of New York,
Amherst, New York
Evidence for a New Mechanism of
IVIG Action, October 2002, The University of Michigan,
Department of Pharmaceutical Sciences, College of Pharmacy, Ann
Arbor, Michigan
Bioreactor Accelerated
Immunotoxicotherapy, August 2002, Industrial Science &
Technology Network Inc., York, Pennsylvania
Investigation of IVIG Mechanism
of Action in ITP: Application of new findings to identify
targets for therapy, June 2002, The University of Michigan, Yang
Laboratory, Department of Pharmaceutical Sciences, College of
Pharmacy, Ann Arbor, Michigan
Application of Kinetic – Dynamic
Modeling to Predict Antibody Effects in an Inverse Targeting
Strategy, May 2002, University of North Carolina, Division of
Drug Delivery and Disposition, College of Pharmacy, Chapel Hill,
North Carolina
Case Study: Application of PK/PD
Modeling to Delineate Mechanisms of IVIG Action in Immune
Thrombocytopenia, May 2002, Georgetown University Center for
Drug Development Science: Workshop on ‘Physiologically Based
Pharmacokinetics in Drug Development and Regulatory Science’,
Washington, DC
Monoclonal Antibodies, May 2002,
University at Buffalo – Leiden/Amsterdam Center for Drug
Research Pharmacokinetic – Pharmacodynamic Concepts and
Applications Course, Buffalo, New York
New Insights Into the Mechanism
of IVIG Action in Immune Thrombocytopenia, April 2002,
University of Kentucky, Division of Pharmaceutical Sciences,
College of Pharmacy, Lexington, Kentucky
Pharmacokinetics and
Pharmacodynamics of Monoclonal Antibodies, May 2001, University
at Buffalo – Leiden/Amsterdam Center for Drug Research
Pharmacokinetic – Pharmacodynamic Concepts and Applications
Course, Buffalo, New York
Pharmacokinetics and
Pharmacodynamics of Antibodies, May 2000, University at Buffalo
– Leiden/Amsterdam Center for Drug Research Pharmacokinetic –
Pharmacodynamic Concepts and Applications Course, Buffalo, New
York
Pharmacology and Bioengineering
of New Treatments for Immune Thrombocytopenia, January 2000, The
University of Michigan, Yang Laboratory, Department of
Pharmaceutics, College of Pharmacy, Ann Arbor, Michigan
Animal Models of Immune
Thrombocytopenia: Application for the Development and Evaluation
of New Treatments for ITP, January 2000, University at Buffalo,
Department of Pharmaceutics, Buffalo, New York
Inverse Targeting: New
Approaches of Enhancing the Selectivity of Ovarian Cancer
Chemotherapy, August 1999, University at Buffalo, Department of
Pharmaceutics, Buffalo, New York
Inverse Targeting: A New
Approach for Enhancing the Selectivity of the Chemotherapy of
Peritoneal Tumors, July 1999, Huntsman Cancer Institute, Salt
Lake City, Utah
Understanding the Influence of
Drug Formulation on PK/PD: Introduction of a New
Inverse-Targeting Approach, May 1999, Lipocine Inc., Salt Lake
City, Utah
Optimization of Cancer
Chemotherapy, February 1999, Utah State University, Department
of Chemistry, Logan, Utah
Optimization of intraperitoneal cancer chemotherapy with
anti-drug antibodies: Pharmacokinetic rationale and experimental
results, November 1995, American Association of Pharmaceutical
Scientists, Eli Lilly Graduate Symposium, Miami, Florida
.
|
